James Peyer Buys 10,845 Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Director James Peyer bought 10,845 shares of the stock in a transaction on Tuesday, January 11th. The stock was purchased at an average price of $5.18 per share, for a total transaction of $56,177.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

James Peyer also recently made the following trade(s):

  • On Tuesday, December 28th, James Peyer bought 11,288 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $5.28 per share, for a total transaction of $59,600.64.
  • On Thursday, December 23rd, James Peyer bought 11,000 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $5.27 per share, for a total transaction of $57,970.00.
  • On Friday, December 17th, James Peyer bought 117 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $5.29 per share, for a total transaction of $618.93.

NASDAQ SNSE opened at $5.24 on Friday. Sensei Biotherapeutics, Inc. has a 1 year low of $4.70 and a 1 year high of $26.50. The company’s 50 day simple moving average is $6.69 and its two-hundred day simple moving average is $8.15.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its earnings results on Monday, November 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.07). As a group, research analysts forecast that Sensei Biotherapeutics, Inc. will post -1.37 EPS for the current fiscal year.

Several large investors have recently modified their holdings of SNSE. Citigroup Inc. increased its holdings in shares of Sensei Biotherapeutics by 565.5% in the 3rd quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock worth $25,000 after buying an additional 2,047 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Sensei Biotherapeutics by 255.1% in the 3rd quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock worth $25,000 after buying an additional 1,732 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Sensei Biotherapeutics by 37.2% in the 2nd quarter. New York State Common Retirement Fund now owns 5,396 shares of the company’s stock worth $53,000 after buying an additional 1,462 shares during the last quarter. Morgan Stanley bought a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $96,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Sensei Biotherapeutics by 365.6% during the 2nd quarter. Wells Fargo & Company MN now owns 11,081 shares of the company’s stock valued at $108,000 after purchasing an additional 8,701 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response.

Featured Article: How Investors Can Profit from Options Trading

Insider Buying and Selling by Quarter for Sensei Biotherapeutics (NASDAQ:SNSE)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.